CD33 and diffuse large B-cell lymphoma: As we observed a significantly reduced quantity of PD-1+ TILs, an increased quantity of CD33+ cells, and a high possibility of non-CR to treatment related to a low quantity of FOXP3+ cells in our study, we propose that the prognosis of A-DLBCL is poorer than that of ordinary DLBCL.